Alys Pharmaceuticals on the Move: FDA Clears IND for Phase 2a Trial of ALY-101 in AA
The U.S. Food and Drug Administration (FDA) and Health Canada have cleared the Investigational New Drug (IND) / Clinical Trial Application (CTA) for the study of Alys Pharmaceuticals, Inc.’s ALY-101 in alopecia areata (AA). The Phase 2a trial will evaluate the safety and efficacy of ALY-101, an intradermal injectable Janus kinase (JAK)1 small interfering RNA […]